[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Stereotaxis Inc (STXS)

Stereotaxis Inc (STXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 169,085
  • Shares Outstanding, K 97,737
  • Annual Sales, $ 32,380 K
  • Annual Income, $ -21,640 K
  • EBIT $ -22 M
  • EBITDA $ -21 M
  • 60-Month Beta 1.34
  • Price/Sales 5.37
  • Price/Cash Flow N/A
  • Price/Book 12.56

Options Overview Details

View History
  • Implied Volatility 96.59% (-22.96%)
  • Historical Volatility 43.27%
  • IV Percentile 30%
  • IV Rank 13.55%
  • IV High 404.93% on 03/09/26
  • IV Low 48.26% on 08/11/25
  • Expected Move (DTE 29) 0.7140 (41.27%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 13
  • Volume Avg (30-Day) 137
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 2,394
  • Open Int (30-Day) 5,613
  • Expected Range 1.0160 to 2.4440

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.03
  • Number of Estimates 1
  • High Estimate $-0.03
  • Low Estimate $-0.03
  • Prior Year $-0.05
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7000 +1.76%
on 05/19/26
2.0200 -14.36%
on 04/23/26
-0.3000 (-14.78%)
since 04/17/26
3-Month
1.7000 +1.76%
on 05/19/26
2.3450 -26.23%
on 03/05/26
-0.3500 (-16.83%)
since 02/19/26
52-Week
1.7000 +1.76%
on 05/19/26
3.5900 -51.81%
on 10/09/25
-0.3600 (-17.22%)
since 05/19/25

Most Recent Stories

More News
Stereotaxis Q1 Earnings Call Highlights

Stereotaxis (NYSEAMERICAN:STXS) said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products and...

STXS : 1.7300 (-2.81%)
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe Synchrony digital operating...

STXS : 1.7300 (-2.81%)
Stereotaxis Announces First MAGiC Procedures in the United States

ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients...

STXS : 1.7300 (-2.81%)
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will...

STXS : 1.7300 (-2.81%)
Stereotaxis Announces Definitive Agreement to Acquire Robocath

ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced...

STXS : 1.7300 (-2.81%)
Stereotaxis Announces FDA Clearance and Launch of Synchrony System

ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has...

STXS : 1.7300 (-2.81%)
Stereotaxis Reports 2025 Full Year Financial Results

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results...

STXS : 1.7300 (-2.81%)
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will...

STXS : 1.7300 (-2.81%)
Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of...

STXS : 1.7300 (-2.81%)
Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S....

STXS : 1.7300 (-2.81%)

Business Summary

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to allow physicians to navigate catheters, guidewires...

See More

Key Turning Points

3rd Resistance Point 1.8533
2nd Resistance Point 1.8167
1st Resistance Point 1.7733
Last Price 1.7300
1st Support Level 1.6933
2nd Support Level 1.6567
3rd Support Level 1.6133

See More

52-Week High 3.5900
Fibonacci 61.8% 2.8680
Fibonacci 50% 2.6450
Fibonacci 38.2% 2.4220
Last Price 1.7300
52-Week Low 1.7000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.